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Introduction: The optimal approach to patients with malignant airway 
obstruction who require intubation and mechanical ventilation but are 
ineligible for bronchoscopic interventions is uncertain. Radiotherapy 
(RT) may be delivered but requires substantial resources in this patient 
population. In the absence of evidence, it is unknown whether RT facil-
itates extubation or delays an appropriate transition to end-of-life care.
Methods: We performed a 10-year retrospective review of intensive 
care unit (ICU) patients treated with RT while on mechanical ven-
tilation for malignant airway obstruction. Primary study endpoints 
were overall survival (OS) and extubation success (ES), defined as 
48 hours or more without reintubation or death. Secondary endpoints 
included rates of discharge from the ICU and to home. Logistic 
regression and Cox regression analyses were performed to identify 
factors associated with OS and ES.
Results: Twenty-six patients were eligible for analysis. Seven 
patients (27%) were extubated; extubations occurred between days 4 
and 22 after RT initiation. All patients were discharged from the ICU 
and most (n = 6) were also discharged home. An association between 
higher radiation doses and ES was observed (odds ratio per 5 Gy 
increase: 0.63; p = 0.080). Median OS was only 0.36 months (range, 
0–113 months), and 6-month OS was 11%. On Cox regression analy-
sis, increased radiation dose was predictive of improved OS (hazard 
ratio per 5 Gy increase: 0.74; p = 0.016).
Conclusions: A significant minority of patients receiving RT were 
successfully extubated. Higher radiation doses were predictive of 
improved OS and showed a trend for increased ES. Survival beyond 
6 months was uncommon, however, the majority of patients with ES 
were able to be discharged home.
Key Words: Radiotherapy, Malignant airway obstruction, Intensive 
care unit.
(J Thorac Oncol. 2013;8: 1365–1370)
Intensive care unit (ICU) use is on the rise among acutely ill cancer patients in North America.1,2 Malignant airway 
obstruction (MAO) is a common cause of ICU admission, 
often because of lung cancers, lymphoma, or other thoracic 
malignancies.3 Severe cases of MAO are life threatening, and 
although therapeutic bronchoscopic intervention (such as 
debridement or stent insertion)4 may assist in restoring air-
way patency and facilitating extubation, many patients are 
 ineligible for such intervention.
For patients requiring intubation and mechanical ven-
tilation (MV) because of MAO, the efficacy of radiotherapy 
(RT) for achieving extubation is unknown. Although exter-
nal beam RT is a cornerstone of palliative treatment for lung 
cancer,5 the use of RT in intubated patients is uncertain, with 
challenges surrounding safe patient transport, reproducibility 
of setup, overall treatment efficacy, and the cost–benefit ratio.
There is little evidence to guide the use of RT in intu-
bated patients with MAO, and to our knowledge no previous 
studies have examined RT efficacy in this setting. The delivery 
of RT may merely prolong ICU stays, increase costs, and delay 
a proper transition to end-of-life care planning. The goal of 
this study is to assess the efficacy of RT for facilitating extu-
bation and discharge home of ICU patients intubated because 
of MAO and to provide evidence to guide management of this 
challenging patient population.
MATERIALS AND METHODS
Study Design, Population, and Setting
In this institutional ethics review board–approved study, 
we performed a retrospective review of patients treated at the 
London Health Sciences Center (London, Ontario) between 
January 2000 and May 2011 who received RT as cancer treat-
ment while admitted to the ICU. The London Health Sciences 
Center is a tertiary medical and surgical referral center with 
a catchment area of approximately 1.5 million people, and 
includes both an ICU and a cancer center within the same 
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hospital. The Oncology Patient Information System database 
of all cancer patients in the province of Ontario was queried 
based on ICU admission, cancer diagnoses, and RT billing 
codes to identify charts for review.
A total of 82 patients were identified for review. Identified 
patients included those who had a malignancy and received 
RT at some point during their ICU admission. The process 
by which patients were excluded from the study is outlined in 
Supplementary Figure 1 (Supplementary Digital Content 1, 
http://links.lww.com/JTO/A466). Excluded patients included 
those who did not have an MAO (n = 34); those who did have 
an MAO and were sick enough to require ICU admission but 
never needed MV (n = 11); and those that had an MAO and 
needed MV but the intubation and ventilation was not directly 
related to the obstruction (e.g., intubated for bronchoscopy; 
n = 9). The review identified 26 patients for study inclusion, 
who had MAO that necessitated intubation and MV in the 
ICU, and were subsequently treated with RT while on MV. 
At our center, it is our policy that patients with MAO requir-
ing ICU care are assessed by specialists from thoracic surgery 
for consideration of bronchoscopic intervention. Our study 
included only patients who did not receive such interventions. 
Data abstracted included details on patient demographics, RT 
treatment protocol, other concurrent cancer therapies, diagno-
sis (date, site of origin, pathology), extent of disease (staging), 
location of obstruction, previous cancer treatment (surgery, 
chemotherapy, RT), subsequent cancer treatment, length of 
stay in the ICU, and discharge disposition.
Primary and Secondary Endpoints
Primary study endpoints were defined a priori and 
included overall survival (OS), defined as date of RT com-
mencement to date of last follow-up or death, and extubation 
success (ES), which was defined as 2 days or more of extu-
bation without reintubation or death occurring.6,7 Secondary 
endpoints included discharge from ICU and discharge home.
Statistical Analysis
Baseline characteristics of patients in the ES and extuba-
tion-failure groups were compared using the Wilcoxon rank sum 
test for continuous variables and the χ2 test (or Fisher’s exact test 
where appropriate) for categorical variables. Kaplan–Meier esti-
mates of OS and ES were stratified and compared according to: 
sex, age, history of smoking, and/or chronic obstructive pulmo-
nary disease, and tumor stage using the log-rank test. Univariable 
Cox and logistic regression models were performed to examine 
the relationship between individual predictors of OS and ES, 
respectively. Multivariable Cox regression and logistic regression 
modeling were not performed because of small sample size and 
limited number of events. All statistical analyses was performed 
using SAS (version 9.2, SAS Institute, Cary, NC), using two-
sided statistical testing at the 0.05 significance level.
RESULTS
Baseline Characteristics
The mean patient age was 66.2 years, and nearly all 
patients had primary lung cancer (96%). For the majority of 
patients (88%), MAO was either the first presentation of a 
patient’s cancer or occurred while a patient was being actively 
investigated for cancer but had not yet commenced treat-
ment. Additional patient characteristics are shown in Table 1. 
Patients waited an average of 2.9 days (±4.5) from intubation 
and MV until receiving RT. Prescribed radiation dose was 
slightly higher than actual delivered radiation dose (mean, 
19.6 versus 17.9 Gy), as 17 patients were prescribed 20 Gy 
or more but only 13 patients actually received this dosage. 
TABLE 1.  Baseline Patient Characteristics
Characteristic All Patients
Age at treatment (yr), mean ± SD 66.2 ± 10.0
 Median (range) 68 (48–84)
  <60, n (%) 7 (26.9)
  60–69, n (%) 9 (34.6)
  ≥70, n (%) 10 (38.5)
Sex, n (%)
 Male 17 (65.4)
 Female 9 (34.6)
Smoking status, n (%)
 Yes 22 (84.6)
 No 4 (15.4)
COPD history, n (%)
 Yes 18 (69.2)
 No 8 (30.8)
Lung primary, n (%)
 Yes 25 (96.2)
 No 1 (3.9)
Histology, n (%)
 Non–small-cell lung 21 (80.8)
 Small-cell lung 4 (15.4)
 Lymphoma 1 (3.8)
SVCO, n (%)
 Yes 3 (11.5)
 No 23 (88.5)
Hemoptysis, n (%)
 Yes 5 (19.2)
 No 21 (80.8)
Tumor stage, n (%)
 II 4 (15.4)
 III 7 (26.9)
 IV 15 (57.7)
Obstruction location, n (%)
 Right upper lobe 16 (61.5)
 Right middle lobe 3 (11.5)
 Right lower lobe 2 (7.7)
 Left upper lobe 5 (19.2)
 Left lower lobe 2 (7.7)
 Mediastinum 17 (65.4)
 Right mainstem 17 (65.4)
 Left mainstem 6 (23.1)
 Trachea 7 (26.9)
SVCO, superior vena cava obstruction; COPD, chronic obstructive pulmonary disease.
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Two patients had previously undergone surgical resection, 
and another patient previous chemotherapy.
Extubation Success
Seven patients were successfully extubated, yielding a 
crude ES rate of 27%. These extubations occurred between 4 
and 22 days after the initiation of RT. The median number of 
days between initiating RT and ES was 8. The actuarial 10-, 
20-, and 30-day percentages of ES (with patients who were not 
extubated censored at death) were 24.6%, 45.0% and 56.0%, 
respectively (Fig. 1). Patients achieving ES received a higher 
median dose of RT (22.0 versus 12.5 Gy; p = 0.036). There 
were no other significant differences in baseline patient or 
treatment characteristics between individuals who were suc-
cessfully extubated and those who were not. On univariable 
logistic regression modeling, no patient, disease, or treatment 
factor was found to be significantly predictive of ES (Table 2), 
although there was a trend for an association between higher 
radiation dose delivered and successful extubation (odds ratio 
per 5 Gy increase: 0.63; p = 0.080). Of the patients achieving 
ES, RT was successful in controlling hemoptysis in three 
patients, and allowed for the further administration of che-
motherapy in an additional three patients (Supplementary 
Table 1, Supplementary Digital Content 2, http://links.lww.
com/JTO/A467).
Overall Survival
OS was poor, with a median OS of 0.36 months and a 
minority of patients (11%) surviving beyond 6 months (Fig. 2). 
On Kaplan–Meier analysis, patients receiving more than 20 Gy 
had a significantly improved OS (Fig. 3; p = 0.043). Similarly, 
on univariable Cox regression analysis, increased radiation 
dose (hazard ratio per 5 Gy increase: 0.74; p = 0.016) was 
predictive of improved OS (Table 3). One patient was found to 
have lymphoma and was treated with chemotherapy after ES 
and has survived for nearly 10 years.
FIGURE 1.  Actuarial rate of ES measured in days after initiat-
ing RT. ES, extubation success; RT, radiotherapy.
TABLE 2.  Univariable Logistic Regression Models Examining 
Relationship between Individual Predictors of ES
Univariable Odds 
Ratio (95% CI)
p
Age (per 10 unit increase) 0.54 (0.21–1.38) 0.199
Radiation dose (per 5 Gy increase) 1.59 (0.95–2.66) 0.080
Male (ref: female) 4.36 (0.44–43.70) 0.210
COPD history (ref: no) 0.48 (0.08–2.92) 0.422
Smoking status (ref: no) 0.29 (0.03–2.65) 0.275
Small-cell lung cancer (ref: no) 0.89 (0.08–10.30) 0.925
Superior vena cava obstruction (ref: no) 1.42 (0.11–18.60) 0.791
Hemoptysis (ref: no) 6.38 (0.79–51.78) 0.083
Tumor stage (ref: II) III or IV 0.74 (0.14–3.84) 0.715
ES, extubation success; ref, reference; COPD, chronic obstructive pulmonary 
disease; CI, confidence interval.
FIGURE 2.  Kaplan–Meier estimate of OS for the study popu-
lation. OS, overall survival.
FIGURE 3.  OS stratified by patients treated receiving more 
than and less than 20 Gy, p = 0.043. OS, overall survival, 
Gy, Gray.
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DISCUSSION
Management of intubated patients with MAO in the 
ICU is a challenging clinical situation with a paucity of data in 
the medical literature to guide care. Rates of ICU use among 
lung cancer patients are increasing in North America,1,2,8–10 
and estimates indicate that up to 30% of lung cancer patients 
will develop MAO during the course of their disease.4 RT may 
be delivered but requires substantial resources in the form of 
continued ICU support and daily transportation to facilitate 
RT. In the absence of evidence, it is unknown whether RT 
facilitates extubation or rather delays an appropriate transition 
to end-of-life care. To our knowledge, the present study is the 
first to evaluate the efficacy of RT for intubated MAO patients 
in the ICU, and demonstrates that a substantial minority of 
patients can achieve ES within a reasonable timeframe and 
ultimately be discharged home.
Lung cancer accounts for 16% of all cancer-related 
ICU admissions, the highest of any solid malignancy,11,12 with 
data suggesting that one third of lung cancer patients admit-
ted to the ICU have a reversible condition.8 Our results are 
congruent with this, in that 27% of patients had ES and were 
discharged from the ICU. However, median OS was poor and 
most extubated patients died within 6 months. Although there 
is no consensus regarding futility in the medical context,13,14 it 
is typically quantitatively defined as a chance of benefit of 1% 
or less.15 Therefore, RT is not futile in this patient population 
as meaningful endpoints are achieved in more than a quarter of 
the cases. RT should be offered as a treatment option where fea-
sible. In support of this, recent studies suggest that more aggres-
sive lung cancer treatment in the ICU translates to improved 
outcomes, when compared with findings of older studies.16,17 It 
is important to temper this knowledge with the realization that 
most patients will not be extubated and long-term survival is 
uncommon, and so a measured approach is necessary.
A testament to the necessity of a measured approach is 
the finding in a previous retrospective report that the majority 
of lung cancer patients admitted to the ICU are initially cat-
egorized as “full resuscitation” but 49% have their code sta-
tuses changed to “do not resuscitate” over the course of their 
admission.18,19 This, along with the historically poor outcomes 
of these patients,7,18,20,21 and the rising costs associated with 
critical care,8,22 have led some to question the appropriateness 
of ICU admission in this patient population. Ideally, patients 
outline end-of-life care directives such that their wishes are 
clear in the event they are unable to communicate them prop-
erly. However, although the proportion of patients with end-
of-life care directives seems to be on the rise,23 the absolute 
number remains low.24 In the absence of an advanced direc-
tive, which can often be the case in a medical emergency, 
the standard clinical response to severe MAO is to provide 
respiratory support, often via intubation and MV. From this 
point, unrestricted care may be provided for 48 to 72 hours, 
wherein the potential reversibility of the clinical presentation 
is assessed and a definitive treatment plan is implemented in 
discussion with the patient’s family and the multidisciplinary 
team.25–27 However, discordance between health care provid-
ers and families on optimal decision making when faced with 
life-threatening illnesses has been well described,28 and can 
lead to conflict.29 It is therefore imperative for physicians and 
caregivers to agree on when treatment is futile and for discus-
sions about the continued need for MV to be responsive to 
the ever-shifting clinical picture. This current study provides 
useful data to guide these discussions in that it suggests a 
“window” in which MV may reasonably be continued after 
commencing RT, in that all successful extubations occurred 
between 4 and 22 days after the initiation of RT.
RT is a cornerstone of palliative care for advanced 
lung cancer, providing symptom relief and potential benefit 
in terms of OS.5 As with any intervention, however, it is cru-
cial to weigh the risks and benefits in the context of the indi-
vidual patient. This is especially true in critically ill patients 
who require daily transport from the secure environment of 
the ICU to the RT suite. A 2-year review of all ICU cancer 
patients at the Memorial Sloan-Kettering Cancer Center found 
that when compared with nontransported patients, transported 
patients had a greater use of vasopressors, MV, lengthier ICU 
and hospital admissions, and higher hospital mortality.30 An 
analysis from the Australian Incident Monitoring Study in 
Intensive Care found that of the 176 incident reports on intra-
hospital transfers for diagnostic or therapeutic interventions, 
31% resulted in an adverse event: including, severe physi-
ologic derangement (15%), patient/relative dissatisfaction 
(7%), and death (2%).31 Additionally, equipment-related prob-
lems were reported, including difficulties with battery/power 
supply, intubation equipment, transport ventilators, oxygen 
supplies, and monitors. These potential complications must be 
considered when evaluating whether RT would be beneficial 
for a given patient.
Other major modalities for treating MAO include stent 
insertion, laser resection, or surgical debridement.26,32–37 In 
non–small-cell lung cancer patients with MAO requiring intu-
bation and MV, bronchoscopic intervention has been reported 
to facilitate ES in as high as 75% of patients.26 It is standard 
practice in our institution to refer patients with MAO to 
Thoracic Surgery for consideration of stenting. None of the 
patients in this study group received stents and thus it was 
RT that facilitated ES. Chemotherapy for the relief of MAO 
TABLE 3.  Univariable Cox Regression Models Examining 
Relationship between Individual Predictors of OS
Univariable Hazard 
Ratio (95% CI)
p
Age (per 10 unit increase) 1.39 (0.88–2.20) 0.164
Radiation dose (per 5 Gy increase) 0.74 (0.57–0.94) 0.016
Male (ref: female) 0.84 (0.36–1.96) 0.688
Smoking status (ref: no) 1.92 (0.57–6.53) 0.295
COPD history (ref: no) 1.29 (0.53–3.14) 0.579
Small-cell lung cancer (ref: no) 1.00 (0.34–2.95) 0.995
Superior vena cava obstruction (ref: no) 0.75 (0.22–2.58) 0.642
Hemoptysis (ref: no) 0.88 (0.33–2.37) 0.800
Tumor stage (ref: II) III or IV 2.72 (0.80–9.30) 0.110
OS, overall survival; ref, reference; COPD, chronic obstructive pulmonary disease; 
CI, confidence interval.
Bold indicates statistically significant finding.
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because of small-cell lung cancer has also been described 
in the literature. In a small retrospective review, two of five 
small-cell lung cancer patients who received chemotherapy 
while intubated because of MAO achieved ES and were alive 
7 months later.38 Beyond the benefits of extubation and ICU 
discharge, finding the best modality to treat a given patient’s 
MAO can also facilitate further cancer treatment,21,36 which in 
one study translated into a median OS benefit.34 In the pres-
ent study, ES allowed for the further administration of chemo-
therapy in three patients, which was ultimately curative for a 
patient with lymphoma.
The conclusions of this study must be considered in 
the context of its limitations. First, although this study uses 
data from over a 10-year period at a large tertiary care center, 
the sample size is small because of the relatively uncom-
mon nature of the clinical scenario. This limits the power 
of the study to analyze all relationships between baseline 
factors and outcomes and to conduct multivariable analysis. 
Second, the patients reported herein comprise only a fraction 
of a larger group of patients with MAO in the ICU requir-
ing MV, who were either (1) not referred for RT treatment 
because of variability in intensivist practice patterns, or (2) 
referred for treatment but did not receive RT because of the 
radiation oncologist’s reluctance to treat, or (3) offered RT 
but did not proceed because of variability in patient deci-
sion making. Third, as is common with retrospective stud-
ies, information pertaining to premorbid function is often 
difficult to evaluate. We cannot exclude the possibility that 
unidentified confounders may have affected extubation and 
survival outcomes. Further data are needed to validate the 
results reported herein.
In conclusion, the results of our study suggest that 
although median survival is poor, RT is not futile for intubated 
patients with MAO, with ES achieved in over one quarter of 
patients. The risks associated with patient transportation, the 
costs of prolonging the ICU stay, and a potential delay in tran-
sition to end-of-life care must be balanced against the poten-
tial for RT to facilitate ES, prolong survival, and potentially 
allow for further cancer treatment. The authors would like to 
emphasize the value of referring patients with this clinical pre-
sentation to Radiation Oncology, especially those ineligible 
for bronchoscopic intervention, so that RT may be considered 
by the multidisciplinary team, patients, and their families.
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